Molecular and Cellular Biology, October 2001, p. 6851-6858, Vol. 21, No. 20
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.20.6851-6858.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Departments of Medicine3 and Medical Biophysics,1 University of Toronto, Princess Margaret Hospital and Ontario Cancer Institute, Toronto, Ontario M5G 2M9, Canada, and Nagoya School of Medicine, Showa-ku, Nagoya 464, Japan2
Received 13 February 2001/Returned for modification 13 March 2001/Accepted 19 July 2001
| |
ABSTRACT |
|---|
|
|
|---|
The mitogen-activated protein kinases (MAPKs) are signaling
molecules that become enzymatically activated through phosphorylation by diverse stimuli. Hematopoietic cytokines, growth factors, and stimulated lymphocyte antigen receptors may activate specific MAPKs by
altering the balance of MAPK-activating protein kinases and the protein
phosphatases that target their activation sites. Hematopoietic protein
tyrosine phosphatase (HePTP) is a hematopoiesis-specific cytoplasmic
protein tyrosine phosphatase whose expression is induced by mitogenic
stimuli. To investigate the role of HePTP in hematopoietic development,
we constructed mice deficient in this phosphatase using the technique
of homologous recombination. Primary lymphocytes from
HePTP
/
mice show enhanced activation of extracellular
stimulus-regulated kinase (ERK) after both phorbol myristate acetate
(PMA) and anti-CD3-mediated T-cell receptor (TCR) stimulation,
suggesting a true physiological relationship between these two
molecules. Activation of MEK, the physiological activator of ERK, by
anti-CD3 or PMA is not affected by HePTP deletion. The distribution of
hematopoietic lineages in bone marrow and peripheral blood samples and
the in vitro proliferative capacity of bone marrow progenitors from
HePTP deletion mice do not deviate from those of matched littermate
controls. Similarly, lymphocyte activation and development are
indistinguishable in HePTP
/
mice and controls. We
conclude that HePTP is a physiological regulator of ERK on the basis of
these studies and hypothesize that its deletion is well compensated for
in the developing mouse through reduction of ERK targets or enhancement
of physiologically opposed signaling pathways.
| |
INTRODUCTION |
|---|
|
|
|---|
Extracellular stimuli modify cells by altering traffic through intracellular networks of protein kinases and related molecules. The mitogen-activated protein kinase (MAPK) family plays a central role in signaling pathways stimulated by extracellular stimuli such as growth factors, cytokines, and physical stress and is conserved over a huge evolutionary distance (8). In higher organisms, this broad kinase family includes the extracellular stimulus-regulated kinases (ERKs) and two stress-stimulated kinase groups, the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and the p38HOG kinases (2, 11, 19, 33).
In response to specific stimulation, the MAPKs are activated by phosphorylation on conserved threonine and tyrosine amino acids which are found within an activation motif (27, 28, 31). This critical regulation site is located in a loop linking kinase domains VII and VIII and varies in length between individual MAPKs (13, 16). Both the length of this loop and the identity of adjacent amino acids determine the specificity of MAPK kinases, which are the principal determinants of MAPK activity (16, 43).
While extracellular stimuli may induce activating phosphorylation of MAPKs by activating MAPK kinases, the MAPK-specific dual specificity protein phosphatases are potential negative regulators of mitogenic cascades by targeting these same sites (24, 25, 35). These nuclear MAPK phosphatases are typified by MAPK phosphatase 1 (MKP-1), which targets both phosphothreonine and phosphotyrosine on most activated MAPKs. Its overexpression can counter the transforming action of Ras activation in fibroblasts (35), presumably by dephosphorylating activated ERK, antagonizing the activity of MAPK kinases directly. The dual-specificity phosphatases MKP-3 and MKP-4 also inactivate the ERKs, while the phosphatase M3/6 may have specificity for the SAPK/JNK family (24, 25). Similarly, the neuronal ERK tyrosine-specific phosphatases phosphoprotein phosphatase (PTP-SL) and striatum-enriched phosphatase-SL (STEP) associate with ERK through a specific docking site, termed the kinase interaction motif (KIM), resulting in specific ERK inactivation through tyrosine dephosphorylation (29).
Important signaling events may reflect the balance between MAPK kinases and MAPK phosphatases. MAPK phosphatases may be controlled as part of a coordinated cellular response to extracellular signals. For example, stress stimuli, acting through the JNK (SAPK) family of MAPKs, induce the expression of MKP-1, which targets sites of activating phosphorylation on ERK (4). Such cross-regulation may act to prevent the activation of physiologically conflicting pathways after multiple stimuli. Alternatively, MAPK phosphatases may be activated in parallel to their targets, causing the activation of these powerful signaling molecules to be self-limited. For instance, the MAPK phosphatase MKP-3 is activated after phosphorylation of ERK-2 by binding of ERK-2 to the noncatalytic amino terminus of MKP-3 (6).
We have described a hematopoiesis-specific protein tyrosine phosphatase (HePTP) that is induced in primary lymphocytes by extracellular stimuli such as the mitogens concanavalin A, phytohemagglutinin, and interleukin-2 (IL-2) and by gene transfer of activated Lck or c-Raf (1, 44). Overexpression of HePTP reduces T-cell receptor (TCR)-induced activation of ERK2 and blocks TCR-induced transcriptional activation of an interleukin-2 promoter-derived ERK-responsive element (32). Overexpression of HePTP also reduces ERK activation after phorbol myristate acetate (PMA) or TCR stimulation of cultured Jurkat cells and interferes with PMA- and growth factor-induced MAPK activation in myeloid cells. Consistent with its role as an ERK phosphatase, HePTP contains a KIM, as observed in PTP-SL and STEP (29). Collectively these data suggest that HePTP may have a unique role in hematopoietic mitogenic signaling cascades, possibly through direct ERK dephosphorylation.
While existing data suggest that HePTP may be an ERK tyrosine
phosphatase, studies based on gene transfer-induced overexpression and
in vitro enzymatic reactions often do not identify true physiological activities. For example, MEKK1, a mammalian kinase related to the
Saccharomyces cerevisiae pheromone signaling kinase Ste11, was initially identified through cell transfection experiments as an
activator of the ERK kinase MEK (from which it derives its name)
(20). Subsequent studies demonstrated that MEKK-1 is
unlikely to be a physiologic activator of MEK-1, having much higher
specificity for SEK-1, the upstream activator of the SAPK/JNK family
(42). To further characterize the role of HePTP in
hematopoietic cell signaling, we generated mice deficient in this
enzyme using the technique of homologous recombination. We report here
that HePTP
/
mice are fertile and healthy in
appearance, with normal solid organ and bone marrow morphology. Despite
increased ERK activation observed after PMA or TCR stimulation of
HePTP
/
lymphocytes, proliferative response
and cytokine secretion are normal. This work demonstrates that HePTP is
a physiologically relevant ERK hematopoietic phosphatase, though its
absence appears to be well compensated for in genetically deficient mice.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Generation of mice genetically deficient in HePTP.
A plasmid
used to introduce a targeted HePTP mutation by homologous recombination
was constructed by inserting the pMC1Neo gene cassette between the
PstI site in exon 2 and the BglII site found in
the second intron of the HePTP gene. This plasmid was transfected into
the E14K embryonic stem (ES) cell line (kindly provided by K. Rajewsky,
Cologne, Germany) by electroporation. G418-resistant ES clones were
screened by PCR using primers producing products distinguishing
wild-type and mutant forms. Two cell lines with proper homologous
recombination were obtained and verified by Southern hybridization
analysis. Each cell line was injected into blastocysts of C57BL/6 mice
(Jackson Laboratory), producing chimeras. These chimeric mice, derived
from two different ES clones, were mated with C57BL/6 mice. Tail DNA
from offspring with agouti coat color was analyzed by PCR or Southern
hybridization to confirm the germ line integration of the mutated HePTP
gene. Heterozygous mice were mated to generate +/+ and
/
littermates to be used for experimentation. Mice were mated and
maintained in the animal facility of the Ontario Cancer Institute.
Animals were housed in a semibarrier set which includes sterile static
microisolators, acidified (pH 2.8) drinking water by bottle, and
sterile standard laboratory rodent chow. Animal cages were serviced in
HEPA-filtered room air.
/
mice were identified by a 1.8-kb
amplification product, since amplification of template genomic DNA from
HePTP+/+ mice produces a 0.7-kb band.
Lymphocyte proliferation assays. Spleen, thymus, and lymph nodes were surgically removed and meshed to obtain a single-cell suspension. Cells were washed, counted, and cultured in Iscove modified Dulbecco's medium (IMDM) containing fetal calf serum (FCS) (10%). Spleen cells (105/100 µl) were placed in 96-well plates in the presence of anti-CD3E with anti-CD28 (both from PharMingen) (12). Proliferation studies were performed using [3H]dT (1 µCi/well) (NEN) added for 16 h after 24 and 48 h of stimulation. Cells were harvested (Packard Filtermate cell harvester), and the incorporated thymidine was measured on a Top Count NXT (Packard). Cells harvested at different intervals were stained with biotinylated anti-CD69 and anti-CD25 and analyzed using a FACScan (Becton Dickinson).
Hematopoietic colony assay.
Marrow cells were flushed from
the femora of 8- to 12-week-old HePTP+/+ and
HePTP
/
littermate mice. Cells were
resuspended in IMDM, counted, and plated at various concentrations in
methylcellulose (1 ml) containing erythropoietin (1 U) (EPO; Kirin
Brewery), fetal bovine serum (4%; ICN/Flow), bovine serum albumin
(0.5%; Sigma), human transferrin (0.1 mg/ml; Boehringer), recombinant
human IL-11 (rhIL-11) (0.01 µg; Genetics Institute), rhIL-1
(0.001 µg; Biogen), cystine (0.02 mg; Sigma), insulin (0.01 mg; Sigma),
lipids mix (1.6 µl; Sigma), IL-3-containing conditioned medium (15 U), CHO cell line-conditioned medium containing the c-kit ligand (3%),
and 5637 cell line-conditioned medium (10%) (39).
Cultures were incubated for 3 to 10 days at 37°C in a humidified
atmosphere containing CO2 (5%). Myeloid, erythroid, and megakaryocytic colonies were identified morphologically using May-Grunwald-Giemsa staining.
Immunostaining and flow cytometry.
Single-cell suspensions
(106 cells) from thymus, spleen, or
axillary/cervical lymph nodes were resuspended in phosphate-buffered saline (PBS) and incubated for 30 min on ice with phycoerythrin (PE),
fluorescein isothiocyanate (FITC), or biotin-conjugated anti-CD4,
anti-CD8, anti-TCR
, anti-CD3, anti-CD25/IL-2R
, anti-CD28, anti-CD69, anti-CD5, anti-immunoglobulin M (IgM), anti-CD11B, anti-CD45, or anti-B220. Biotinylated antibodies were visualized using
streptavidin-RED670 (Life Sciences). Samples were analyzed using a
FACScan (Becton Dickinson).
Detection of MAPK and MEK phosphorylation in primary mouse lymphoid tissues. Splenocytes, thymocytes, or lymph node cells were washed and incubated in IMDM containing FCS (0.5%) with either anti-CD3E antibody (10 µg/ml) (PharMingen) or PMA (10 nM) (Sigma) to induce ERK pathway activation. Sorbitol (400 mM) was used to induce p38HOG and SAPK activation. Cells (2 × 107) were placed in lysis buffer (200 µl) consisting of Nonidet P-40 (0.1%), Tris (pH 7.5) (50 mM), NaCl (150 mM), sodium orthovanadate (5 mM), dibasic sodium pyrophosphate (50 mM), and the protease inhibitors leupeptin (1 µg/ml), aprotinin (1 µg/ml), and phenylmethylsulfonyl fluoride (1 mM) (all from Sigma). Protein concentration was measured in each lysate using Bio-Rad reagent. Equal amounts of proteins were analyzed by polyacrylamide gel electrophoresis (PAGE) followed by Western analysis using antibodies specific for the enzymatically activated phospho-specific forms of SAPK, p38HOG, MEK, and ERK1 and -2 (all from New England Biolabs). Western blots to detect total MAPK and MEK were performed to ensure equal loading in each lane.
Capture ELISA.
Lymph node cells from
HePTP+/+ and HePTP
/
mice were cultured in IMDM containing FCS (10%) in the presence of
anti-CD3E (1 µg/ml) plus anti-CD28 (1 µg/ml) (both from
PharMingen). After 24 and 48 h of stimulation, supernatants (100 µl/well) were collected and kept at
70°C for subsequent IL-2
determination. IL-2 levels were measured with the mouse IL-2 Duo Set
enzyme-linked immunosorbent assay (ELISA) development system (R&D)
using a Bio-Rad plate reader.
Th1 and Th2 differentiation.
Spleen cells from
HePTP+/+ and HePTP
/
mice were passed through a stainless steel screen to make single-cell
suspensions. The cells were washed in
minimal essential medium
(
MEM) (Gibco) supplemented with glutamine (2 mM), sodium pyruvate (1 mM), HEPES (pH 7.3) (15 mM), mercaptoethanol (50 µM), and FCS (10%).
Splenocytes (4 × 106 cells) were cultured
for 48 h in 24-well flat-bottomed plates as described
(15), and T cells were activated by incubation with a 1:40
dilution of anti-CD3E monoclonal antibody culture supernatant.
Cultures were harvested, and activated T cells were recovered by
centrifugation with Lympholyte and reactivated by incubation for an
additional 16 h in 96-well plates coated with anti-CD3E
antibody. During the last 3 h of incubation, cells were exposed to
brefeldin A (10 µg/ml; Sigma). Cells were subsequently washed in PBS,
fixed with paraformaldehyde (4%), and permeabilized with saponin
(0.1%). T-cell subsets were identified by flow cytometry using
appropriate concentrations of monoclonal antibodies directed against
CD4, CD8, IL-4, IL-10, tumor necrosis factor alpha (TNF-
), and gamma
interferon (IFN-
) as described (14).
| |
RESULTS |
|---|
|
|
|---|
Generation of HePTP deletion mice.
To further characterize the
physiological role of HePTP, we generated deletion mice through the
process of homologous recombination. Exon 2 of the HePTP gene was
disrupted in E14K embryonic stem cells using a replacement construct
containing the pMC1Neo gene expression cassette (Fig.
1A) (38). The neo
gene was inserted between the PstI site in exon 2 and the
BglII site found in the second intron of the HePTP gene. Two
recombinant ES cell clones were identified by PCR and confirmed on
Southern blotting of DNA (Fig. 1B). Each clone was injected into
blastocysts of C57BL/6 mice, producing chimeras which were mated with
C57BL/6 mice. Tail DNA from offspring with agouti coat color were
analyzed by PCR or Southern hybridization to confirm the germ line
integration of the mutated HePTP gene. Expression of HePTP was tested
by Western analysis of protein extracts from mouse tissues. As shown in
Fig. 1C, expression was totally absent in
HePTP
/
mice, which are fertile and appear
healthy. The distribution of genotypes +/+,
/
, and +/
followed
Mendelian inheritance (data not shown).
|
ERK stimulation is enhanced in HePTP
/
primary
lymphoid cells.
To address the intersection of HePTP and the ERK
signaling cascades, we evaluated PMA-induced ERK and MEK activation in
mouse lymphocytes lacking HePTP. Isolated spleen cells were incubated ex vivo with PMA at various concentrations. Western blot analysis using
antibodies specific for the phosphorylated forms of ERK showed enhanced
phosphorylation in HePTP
/
cells in comparison
to HePTP+/+ cells, while no change in MEK
activation was observed (Fig. 2A). Since
HePTP may inhibit TCR-induced ERK activation (32), ERK and
MEK activity after antibody-induced TCR stimulation of
HePTP
/
lymphocytes was also evaluated.
Lymphocytes incubated with anti-CD3E for 0 to 60 min were immediately
lysed in buffer containing protease and phosphatase inhibitors. Despite
equivalent total ERK expression, TCR-stimulated
HePTP
/
lymphocytes demonstrated enhanced
TCR-mediated ERK phosphorylation. MEK expression and activation were
unchanged (Fig. 2B). When splenic lymphocytes were treated with
sorbitol to induce p38HOG and SAPK activation,
no difference was noted between HePTP
/
and
HePTP+/+ mice, suggesting that ERK but not the
stress-induced kinase cascades are altered in
HePTP
/
mice (Fig. 2C and D). These data
suggest that HePTP is a physiologic downmodulator of TCR-stimulated ERK
activity and does not seem to have an inhibitory effect on the other
MAPKs or on proximal signaling pathways.
|
Myelopoiesis and lymphopoiesis are normal in HePTP
/
mice.
Since ERK stimulation is an important component of
hematopoietic clonal expansion and development, we performed a
quantitative analysis of bone marrow cells in
HePTP+/+ and HePTP
/
mice. Bone marrow samples were stained with May-Grunwald-Giemsa stain,
and differential cell counts were performed. Figure
3 shows that no significant difference
was found in the distribution of cell lineages between wild-type and
HePTP-deleted mice.
|
/
and
HePTP+/+ mice (Fig.
4).
|
/
and HePTP+/+ mice were stained with
hematoxylin-eosin (HE) and studied by light microscopy. Fresh
single-cell suspensions from these organs were also isolated, and
different lymphoid subpopulations were determined by flow cytometry. No
difference in organ architecture between
HePTP
/
and HePTP+/+
mice was observed. Levels of surface expression of all lymphoid markers
were similar in lymphoid organs from both mice, suggesting the
preservation of lymphoid subsets (Table
1).
|
Mitogen-induced expression of activation-induced surface marker and
proliferation are not affected by HePTP deletion.
Since HePTP is
expressed in differentiated blood cells, we examined proliferation and
activation of mature lymphocytes in cells lacking this phosphatase.
Expression of the ERK-dependent activation marker CD69 after PMA or
anti-CD3 stimulation of splenic lymphocytes was evaluated (36,
37). The levels of expression of CD69 were comparable in
HePTP+/+ and HePTP
/
mice (Table 1) (5, 37).
/
cells (Fig. 5). As an additional marker
of T-cell activation, IL-2 production was measured using capture ELISA
after TCR and CD28 stimulation of primary lymphocytes. No significant
difference was found between HePTP
/
and
HePTP+/+ cells in the level of IL-2 produced
(Fig. 6).
|
|
/
mice.
Spleen-derived naive T lymphocytes were stimulated with anti-CD3E
antibody. The production of Th2 cells was assessed by intracellular
cytokine staining with anti-IL-4 and anti-IL-10 antibodies.
Differentiation into Th1 cells was identified by IFN-
and IFN-
expression using flow cytometry analysis. Comparison of
HePTP+/+ and HePTP
/
mouse Th1 subpopulations did not reveal significant differences (data
not shown).
| |
DISCUSSION |
|---|
|
|
|---|
Phosphorylation of signaling protein kinases can stimulate their enzymatic activity, as is observed after MAPK phosphorylation (8), or can be inhibitory, as is seen after phosphorylation of Src family kinases, such as Lck (3). Protein phosphatases are hypothesized to be important counterbalances to the activities of regulatory kinases. Through gene targeting and other techniques, specific physiological roles for some phosphatases are becoming understood. For instance, the tyrosine phosphatase CD45 functions in signaling from the lymphocyte antigen receptors by specifically removing phosphate from a carboxy-terminal inhibitory tyrosine residue from Lck (18, 26). The very restricted pattern of CD45 expression to hematopoietic cells is consistent with such a central role in cell signaling. For few tyrosine phosphatases has such a discrete molecular activity been defined.
The MAPK phosphatase/PAC1 family of dual-specificity phosphatases
target conserved phosphoserine and phosphothreonine residues found
within the activation motif of the MAPKs (17, 21-25, 34, 40-47,
49). MKP-1, the best-characterized member of this growing family, dephosphorylates ERK2, SAPK, and p38HOG
in transient-transfection studies (7). Its expression is
induced in U937 cells by PMA, coincident with the eventual inactivation of ERK and consistent with its presumed role as a MAPK repressor (10). Overexpression of MKP-1 prevents ERK activation and
prevents Ras-induced stimulation of DNA synthesis. Interestingly, mice deficient in this gene, unlike HePTP
/
mice,
still activate ERK normally, suggesting functional redundancy within
this gene family (7, 9, 35). The physiologic role of MKP-1
and others in this family of nuclear dual specificity phosphatases may
be both to reset MAPK signaling pathways and to regulate the relative
traffic through each of them. For example, SAPK activation induces
MKP-1 expression, inhibiting ERK activation, thereby limiting cell
division during times of cell stress (4).
HePTP is expressed only in the cytoplasm of cells of hematopoietic origin, such as mature erythrocytes, macrophages, neutrophils, and megakaryocytes, and also macrophagic progentor cells. Like MKP-1, its expression is induced by mitogens, although the temporal profiles differ. While MKP-1 expression is maximal 4 h after PMA stimulation of U937 cells, significant expression of HePTP is not observed in primary lymphocytes until 24 h after lipopolysaccharide or concanavalin A stimulation (10, 44).
To study the physiological role of HePTP in vivo, we generated and
evaluated mice in which HePTP was disrupted by homologous recombination. We demonstrated that ERK activation in
HePTP
/
mice is enhanced in response to TCR
stimulation and mitogens such as PMA. MEK activation after mitogen
stimulation is not HePTP dependent, suggesting that ERK is a
physiological target for this phosphatase but proximal signaling
elements are unaffected.
Since HePTP is expressed widely in mature hematopoietic cells, we
examined the development and function of bone marrow, peripheral blood,
and lymphoid tissues in HePTP
/
mice. We show
that HePTP
/
mice have normal hematopoiesis,
as indicated by bone marrow cultures. Lymphocyte subset numbers and
function are normal in HePTP
/
mice, as shown
by anti-CD3-induced proliferation and IL-2 production.
Marked physiological derangement of HePTP
/
mice induced by ERK activation may be attenuated through compensatory
biochemical pathways which become induced during development. The
consequences of physiologically inappropriate ERK activation may be
modified through the downregulation of ERK targets or the induction of counterbalancing signaling pathways in HePTP
/
mice. Opposite mechanisms may be operative in mice deficient in
p44ERK1, which appear normal, having only subtle
changes in thymocyte maturation (22). In these mice,
p44ERK2 activation and other alterations may
compensate for the deficiency of this major effector of mitogenic signaling.
While there are many examples of nuclear threonine/tyrosine phosphatases, few cytoplasmic MAPK-targeted phosphatases have been recognized. The neuron-specific tyrosine phosphatases PTP-SL and STEP bind to ERK through a 14-residue KIM, consisting of the consensus motif LQERRGSNVXLXLD (29). These two tyrosine phosphatases extinguish ERK enzymatic activity and are themselves phosphorylated by ERK. HePTP contains the sequence LQERRGSNVALMLD (residues 16 to 30), which is consistent with its ability to associate with ERK (44). These observations suggest that HePTP, PTP-SL, and STEP have similar tissue-specific functions as cytoplasmic regulators of ERK-dependent signaling cascades.
Hematopoietic cells are exposed to a spectrum of antigenic or cytokine stimuli which may potentially induce all three families of MAPKs. ERK stimulation, induced by both growth factors and mitogenic cytokines, often propels cells into division or differentiation, while SAPK and p38HOG activation may be associated with cell growth delay, differentiation, or apoptosis. Additional intracellular mechanisms of MAPK control are needed to integrate potentially conflicting signals and allow a coordinated cell outcome. MAPK phosphatases, such as the MKPs, PAC1, and HePTP, provide an additional layer of regulation over MAPK-induced physiological responses to extracellular stimuli. For instance, prolonged stimulation of hematopoietic cells by inflammatory cytokines, a circumstance in which HePTP is induced, may trigger relative stimulation of the SAPK pathway, since HePTP preferentially inactivates ERK and p38HOG. Unopposed SAPK or p38HOG activation in this circumstance may lead to growth arrest or apoptosis, thus limiting the inflammatory response.
Although HePTP is among the first examples of an inducible tyrosine phosphatase that acts as a mammalian MAPK inhibitor, several have been identified in S. cerevisiae, suggesting phylogenetic conservation of tyrosine phosphatase-induced control of MAPK activation. The Schizosaccharomyces pombe MAPK StyI, like mammalian MAPKs, becomes activated through dual phosphorylation, initiating mitotic fission. StyI is regulated by the MAPK kinase Wis1, which is sensitive to changes in external osmolarity. Under conditions of hyperosmolality, Wis1 induces the transcription of pyp2, a tyrosine phosphatase functionally redundant to pyp1, which specifically targets StyI, resulting in its inactivation (21). Similarly, in budding yeast, the tyrosine phosphatases PTP2 and PTP3 specifically target the Hog1 MAPK, thereby inactivating the response to osmotic stress. Similar to pyp2 in fission yeast, PTP2 and PTP3 are induced by osmotic stress, suggesting that they function in a negative feedback loop (41). We have shown that HePTP is induced by mitotic stimuli such as PMA and concanavalin A in murine lymphocytes (44). The regulation of mitotic signaling by HePTP is in this way similar to the regulation of the yeast hyperosmolar response by PTP2 and PTP3, suggesting conservation of a general signaling mechanism.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the National Cancer Institute of Canada to B. Zanke. We thank T. W. Mak for assistance with homologous recombination experiments, Joseph Penninger for his guidance in experiments evaluating T-cell proliferation and TCR-induced ERK activation, Norman Iscove and Deborah Hyam for assistance with experiments involving the hybridization of lineage blots and culture of mouse bone marrow, Kaliannan Raju for assistance with T-helper 1 and 2 differentiation experiments, and Christine Quarrinton and her team at the OCI Animal Resource Centre for assistance with animal care.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: The Cross Cancer Institute, 51160 University Avenue, Edmonton, Alberta T6G 1Z2, Canada. Phone: (780) 432-8771. Fax: (780) 432-8411. E-mail: zanke{at}cancerboard.ab.ca.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Adachi, M., T. Torigoe, M. Sekiya, Y. Minami, T. Taniguchi, Y. Hinoda, A. Yachi, J. C. Reed, and K. Imai. 1995. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. FEBS Lett. 372:113-118[CrossRef][Medline]. |
| 2. | Ahn, N. G., R. Seger, R. L. Bratlien, and E. G. Krebs. 1992. Growth factor-stimulated phosphorylation cascades: activation of growth factor-stimulated MAPK. CIBA Found. Symp. 164:113-126[Medline]. |
| 3. | Bergman, M., T. Mustelin, C. Oetken, T. Partanen, N. A. Flint, K. E. Amrein, M. Autero, P. Burn, and K. Alitalo. 1992. The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J. 11:2919-2924[Medline]. |
| 4. |
Bokemeyer, D.,
A. Sorokin,
M. Yan,
N. G. Ahn,
D. J. Templeton, and M. J. Dunn.
1996.
Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts.
J. Biol. Chem.
271:639-642 |
| 5. | Borrego, F., J. Pena, and R. Solana. 1993. Regulation of CD69 expression on human natural killer cells: differential involvement of protein kinase C and protein tyrosine kinases. Eur. J. Immunol. 23:1039-1043[Medline]. |
| 6. |
Camps, M.,
A. Nichols,
C. Gillieron,
B. Antonsson,
M. Muda,
C. Chabert,
U. Boschert, and S. Arkinstall.
1998.
Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase.
Science
280:1262-1265 |
| 7. |
Chu, Y.,
P. A. Solski,
R. Khosravi-Far,
C. J. Der, and K. Kelly.
1996.
The mitogen-activated protein kinase phosphatases PAC1: MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation.
J. Biol. Chem.
271:6497-6501 |
| 8. |
Davis, R. J.
1993.
The mitogen-activated protein kinase signal transduction pathway.
J. Biol. Chem.
268:14553-14556 |
| 9. | Dorfman, K., D. Carrasco, M. Gruda, C. Ryan, S. A. Lira, and R. Bravo. 1996. Disruption of the ERP/MKP-1 gene does not affect mouse development: normal MAPK activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13:925-931[Medline]. |
| 10. |
Franklin, C. C., and A. S. Kraft.
1997.
Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells.
J. Biol. Chem.
272:16917-16923 |
| 11. |
Galcheva-Gargova, Z.,
B. Derijard,
I. H. Wu, and R. J. Davis.
1994.
An osmosensing signal transduction pathway in mammalian cells.
Science
265:806-808 |
| 12. |
Greulich, H., and R. L. Erikson.
1998.
An analysis of Mek1 signaling in cell proliferation and transformation.
J. Biol. Chem.
273:13280-13288 |
| 13. |
Hanks, S. K.,
A. M. Quinn, and T. Hunter.
1988.
The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains.
Science
241:42-52 |
| 14. |
Heiskanen, M. A.,
M. L. Bittner,
Y. Chen,
J. Khan,
K. E. Adler,
J. M. Trent, and P. S. Meltzer.
2000.
Detection of gene amplification by genomic hybridization to cDNA microarrays.
Cancer Res.
60:799-802 |
| 15. | Hughes, T. R., C. J. Roberts, H. Dai, A. R. Jones, M. R. Meyer, D. Slade, J. Burchard, S. Dow, T. R. Ward, M. J. Kidd, S. H. Friend, and M. J. Marton. 2000. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat. Genet 25:333-337[CrossRef][Medline]. |
| 16. |
Jiang, Y.,
Z. Li,
E. M. Schwarz,
A. Lin,
K. Guan,
R. J. Ulevitch, and J. Han.
1997.
Structure-function studies of p38 mitogen-activated protein kinase. Loop 12 influences substrate specificity and autophosphorylation, but not upstream kinase selection.
J. Biol. Chem.
272:11096-11102 |
| 17. | Keyse, S. M. 1995. An emerging family of dual specificity MAPK phosphatases. Biochim. Biophys. Acta 1265:152-160[Medline]. |
| 18. | Kishihara, K., J. Penninger, V. A. Wallace, T. M. Kundig, K. Kawai, A. Wakeham, E. Timms, K. Pfeffer, P. S. Ohashi, M. L. Thomas, C. Furlonger, C. J. Paige, and T. W. Mak. 1993. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 74:143-156[CrossRef][Medline]. |
| 19. | Kyriakis, J. M., P. Banerjee, E. Nikolakaki, T. Dai, E. A. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgett. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160[CrossRef][Medline]. |
| 20. |
Lange-Carter, C. A.,
C. M. Pleiman,
A. M. Gardner,
K. J. Blumer, and G. L. Johnson.
1993.
A divergence in the MAPK regulatory network defined by MEK kinase and Raf.
Science
260:315-319 |
| 21. |
Millar, J. B. A.,
V. Buck, and M. G. Wilkinson.
1995.
Pyp1 and Pyp2 PTPases dephosphorylate an osmosensing MAPK controlling cell size at division in fission yeast.
Genes Dev.
9:2117-2130 |
| 22. | Morgan, D. O. 1997. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:261-291[CrossRef][Medline]. |
| 23. |
Muda, M.,
R. Boschert,
R. Dickinson,
J. C. Martinou,
I. Martinou,
M. Camps,
W. Schlegel, and S. Arkinstall.
1996.
MKP-3: a novel cytosolic protein tyrosine phosphatase that exemplifies a new class of mitogen activated protein kinase phosphatase.
J. Biol. Chem.
271:4319-4326 |
| 24. |
Muda, M.,
U. Boschert,
A. Smith,
B. Antonsson,
C. Gillieron,
C. Chabert,
M. Camps,
I. Martinou,
A. Ashworth, and S. Arkinstall.
1997.
Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4.
J. Biol. Chem.
272:5141-5151 |
| 25. |
Muda, M.,
A. Theodosiou,
N. Rodrigues,
U. Boschert,
M. Camps,
C. Gillieron,
K. Davies,
A. Ashworth, and S. Arkinstall.
1996.
The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases.
J. Biol. Chem.
271:27205-27208 |
| 26. |
Mustelin, T.,
K. M. Coggeshall, and A. Altman.
1989.
Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase.
Proc. Natl. Acad. Sci. USA
86:6302-6306 |
| 27. | Payne, D. M., A. J. Rossomando, P. Martino, A. K. Erickson, J. H. Her, J. Shabanowitz, D. F. Hunt, M. J. Weber, and T. W. Sturgill. 1991. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAPK). EMBO J. 10:885-892[Medline]. |
| 28. |
Posada, J., and J. A. Cooper.
1992.
Requirements for phosphorylation of MAPK during meiosis in Xenopus oocytes.
Science
255:212-215 |
| 29. | Pulido, R., A. Zuniga, and A. Ullrich. 1998. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 17:7337-7350[CrossRef][Medline]. |
| 30. |
Roberts, C. J.,
B. Nelson,
M. J. Marton,
R. Stoughton,
M. R. Meyer,
H. A. Bennett,
Y. D. He,
H. Dai,
W. L. Walker,
T. R. Hughes,
M. Tyers,
C. Boone, and S. H. Friend.
2000.
Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles.
Science
287:873-880 |
| 31. | Sanchez, I., R. T. Hughes, B. J. Mayer, K. Yee, J. R. Woodgett, J. Avruch, J. M. Kyriakis, and L. I. Zon. 1994. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-798[Medline]. |
| 32. |
Saxena, M.,
S. Williams,
J. Gilman, and T. Mustelin.
1998.
Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP).
J. Biol. Chem.
273:15340-15344 |
| 33. | Seger, R., and E. G. Krebs. 1995. The MAPK signaling cascade. FASEB J. 9:726-735[Abstract]. |
| 34. | Sun, H., C. H. Charles, L. F. Lau, and N. K. Tonks. 1993. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAPK in vivo. Cell 75:487-493[CrossRef][Medline]. |
| 35. |
Sun, H.,
N. K. Tonks, and D. Bar-Sagi.
1994.
Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1.
Science
266:285-288 |
| 36. | Sutherland, C. L., A. W. Heath, S. L. Pelech, P. R. Young, and M. R. Gold. 1996. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157:3381-3390[Abstract]. |
| 37. |
Terada, K.,
Y. Kaziro, and T. Satoh.
1997.
Ras-dependent activation of c-Jun N-terminal kinase/stress-activated protein kinase in response to interleukin-3 stimulation in hematopoietic BaF3 cells.
J. Biol. Chem.
272:4544-4548 |
| 38. | Thomas, K. R., and M. R. Capecchi. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51:503-512[CrossRef][Medline]. |
| 39. |
Trevisan, M., and N. N. Iscove.
1995.
Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny.
J. Exp. Med.
181:93-103 |
| 40. | Ward, Y., S. Gupta, P. Jensen, M. Wartmann, R. J. Davis, and K. Kelly. 1994. Control of MAPK activation by the mitogen-induced threonine/ tyrosine phosphatase PAC1. Nature 367:651-654[CrossRef][Medline]. |
| 41. | Wurgler-Murphy, S. M., T. Maeda, E. A. Witten, and H. Saito. 1997. Regulation of the Saccharomyces cerevisiae HOG1 mitogen-activated protein kinase by the PTP2 and PTP3 protein tyrosine phosphatases. Mol. Cell. Biol. 17:1289-1297[Abstract]. |
| 42. | Yan, M., T. Dai, J. C. Deak, J. M. Kyriakis, L. I. Zon, J. R. Woodgett, and D. J. Templeton. 1994. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800[Medline]. |
| 43. |
Zanke, B. W.,
E. A. Rubie,
K. Boudreau,
M. McGinnis,
M. Yan,
D. J. Templeton, and J. R. Woodgett.
1996.
Insulation of mammalian MAPK pathways through formation of specific kinase:activator complexes.
J. Biol. Chem.
271:29876-29881 |
| 44. | Zanke, B. W., H. Suzuki, K. Kishihara, L. Mizzen, M. Minden, A. Pawson, and T. W. Mak. 1992. Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur. J. Immunol. 22:235-239[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|